News & Updates

Show Multimedia Only
Relapsed/refractory multiple myeloma patients burdened with poor survival, high costs

Relapsed/refractory multiple myeloma patients burdened with poor survival, high costs

06 Apr 2022

Patients with relapsed/refractory multiple myeloma (RRMM) are at greater risk of adverse events (AEs), have low overall survival (OS), and suffer a substantial economic burden, reports a study, which suggests the need for effective treatment options.

Relapsed/refractory multiple myeloma patients burdened with poor survival, high costs

06 Apr 2022
Continued anti-VEGF use after disease control does not prevent nAMD recurrence

Continued anti-VEGF use after disease control does not prevent nAMD recurrence

06 Apr 2022

In patients with neovascular age-related macular degeneration (nAMD) who achieve functional and morphological disease stability, continuing treatment with antivascular endothelial growth factors (anti-VEGF) does not substantially reduce the risk of recurrence, reports a recent study.

Continued anti-VEGF use after disease control does not prevent nAMD recurrence

06 Apr 2022
Insulin pump, CGM use linked to better glucose control during pregnancy

Insulin pump, CGM use linked to better glucose control during pregnancy

06 Apr 2022